LINATAB E 5/25 (Linagliptin 5 mg + Empagliflozin 25 mg Tablets)

Description

DESCRIPTION:
Linatab E 5/25 is a fixed-dose combination of Linagliptin 5 mg and Empagliflozin 25 mg, belonging to the class of oral antidiabetic medications used in the management of Type 2 Diabetes Mellitus. It is indicated for adult patients whose blood glucose levels are inadequately controlled with diet, exercise, and/or metformin monotherapy.

Type 2 diabetes mellitus is a chronic metabolic disorder in which the body either does not produce enough insulin or cannot effectively utilize it (insulin resistance). Uncontrolled blood sugar levels over time can lead to serious complications such as neuropathy, nephropathy, retinopathy, and cardiovascular diseases.

Linatab E 5/25 combines two complementary mechanisms of action. Linagliptin is a Dipeptidyl Peptidase-4 (DPP-4) inhibitor that works by increasing incretin hormone levels, which help regulate blood glucose by stimulating insulin secretion and suppressing glucagon release after meals. Empagliflozin is a Sodium-Glucose Cotransporter-2 (SGLT2) inhibitor that lowers blood glucose levels by promoting glucose excretion through urine. It also offers additional cardiovascular and renal benefits in patients with type 2 diabetes. Together, these agents effectively reduce both fasting and postprandial blood glucose levels, improve glycaemic control, and support weight and blood pressure reduction.

USES:
For the treatment of Type 2 Diabetes Mellitus in adults. As an adjunct to diet and exercise to improve glycaemic control. May be used as dual therapy or in combination with other antidiabetic agents (e.g., metformin or insulin) as prescribed by a healthcare professional.

MEDICINAL BENEFITS:
Provides a dual mechanism of glucose reduction through both insulin-dependent and insulin-independent pathways. Helps maintain better overall glycaemic control throughout the day. May promote weight reduction and lower systolic blood pressure. Has a low risk of hypoglycaemia when used as monotherapy or with metformin. Demonstrated cardiovascular and renal protection benefits with empagliflozin.

DOSAGE & ADMINISTRATION:
Dosage should be individualized based on the patient’s condition and response. The usual recommended dose is one tablet once daily, taken in the morning with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew. Continue therapy as directed by your physician and do not discontinue without medical advice.

STORAGE:
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children.

WARNINGS & PRECAUTIONS:
Use cautiously. Maintain adequate hydration to prevent dehydration due to increased urination. Monitor for symptoms of urinary tract or genital mycotic infections. Temporarily discontinue before major surgery or in cases of acute illness with reduced food or fluid intake. Avoid alcohol consumption. Use during pregnancy and breastfeeding only if clearly needed and under medical supervision.

SIDE EFFECTS:
Common side effects may include increased urination, urinary tract infection, genital fungal infection, thirst, dehydration, mild hypotension, nasopharyngitis, upper respiratory tract infection, headache, or joint pain. Most effects are mild and resolve on their own. Consult your doctor if any symptoms persist or become bothersome.

DISCLAIMER:
Linatab E 5/25 should be taken strictly under medical supervision. Dosage and duration must be individualized based on blood glucose response and clinical judgement.